Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 32Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

ESR1 Gene Mutation 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 447Surgical Procedures, Operative 164Observation 152Drug Therapy 143Radiotherapy 142Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 79Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 67Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 62Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × elacestrant × Clear all
NCT07563595 2026-05-04

ELENI

iOMEDICO AG

Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

SciClone Pharmaceuticals

Recruiting
350 enrolled
Breast

ESR1 Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡